Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Galmed expands drug development to cancer and heart diseases

Published 19/09/2024, 09:26 pm
GLMD
-

TEL AVIV - Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), a clinical-stage biopharmaceutical company, announced plans to expand its drug development activities to include cancer and cardiometabolic diseases. The expansion follows positive results from the open-label part of its Phase 3 NASH study and recent scientific publications highlighting the role of Stearoyl-CoA desaturase1 (SCD1), the target of Galmed's drug Aramchol, in various diseases.


The company's expansion includes two new programs. The first program will focus on developing Aramchol-based drug combinations to improve treatment outcomes for advanced colorectal and hepatic cancers. The second aims to explore treatments for cardiac fibrosis, a contributor to heart dysfunction and failure. Galmed expects to release new data from in-vitro and ex-vivo studies related to these programs in the fourth quarter of 2024.


Recent scientific findings suggest that SCD1 inhibition could be a promising strategy for treating cardiometabolic diseases, which affect over 60 million people in the United States. Additionally, combining SCD1 inhibitors with standard oncology treatments may help prevent drug resistance, potentially improving the prognosis for patients with certain types of cancer.


Allen Baharaff, President and CEO of Galmed, expressed optimism about the company's direction, emphasizing the significant public health impact of the conditions targeted by their research. Galmed is leveraging two decades of development of Aramchol, an advanced SCD1 inhibitor, to address these major health challenges. The company's approach includes collaborations with academia and industry and the use of innovative methodologies such as AI data mining and "organ-on-a-chip" systems.


Galmed has primarily focused on developing Aramchol for liver diseases but is now exploring its potential in other fibroinflammatory and oncological indications. The company's recent funding activities, which raised $7.5 million through warrant exercises and drawdowns on an equity line, have extended its cash runway, supporting its strategic expansion.


This expansion of Galmed's drug development activities is based on a press release statement and reflects the company's forward-looking plans. These plans are subject to the usual risks and uncertainties associated with clinical trials and regulatory approvals.

InvestingPro Insights


As Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) embarks on an ambitious expansion to tackle cancer and cardiometabolic diseases, investors may want to consider several financial metrics and analyst insights that provide a broader context for the company's strategic direction.


InvestingPro data shows a market capitalization of $4.44 million, reflecting the company's current valuation in the market. Despite challenges, Galmed has demonstrated a significant return over various periods, with a one-week price total return of 73.37%, and even more impressively, a one-month price total return of 91.03%. These figures suggest a recent surge in investor confidence, potentially in response to the company's strategic pivot and positive study results.


However, it's important to note that the P/E ratio stands at -0.46, indicating that the company is not currently profitable, a fact echoed by InvestingPro Tips which state that analysts do not anticipate Galmed will be profitable this year. Additionally, the company's net income is expected to drop this year, and it has not been profitable over the last twelve months. This financial backdrop is crucial for investors to understand as it underscores the high-risk, high-reward nature of investing in clinical-stage biopharmaceutical companies like Galmed.


InvestingPro Tips also highlight that Galmed holds more cash than debt on its balance sheet and that its liquid assets exceed short-term obligations, providing it with a degree of financial stability as it pursues new drug development programs. While the company does not pay dividends, which is common for companies focused on growth and reinvestment, it is worth noting for income-focused investors.


For those looking for additional insights and detailed analysis, there are more InvestingPro Tips available at https://www.investing.com/pro/GLMD, which can help investors make informed decisions about the potential risks and opportunities associated with Galmed's stock.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.